SCHEMBL10262247

SCHEMBL10262247

COc1ccc(-c2cc3c(OCc4ccccc4)cc(Cc4ccccc4)c(-c4ccccc4)c3cc2N2CCOCC2)c(OC)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.39
CDK5 Q00535 1/20 0.39
CDK5R1 Q15078 1/20 0.39
P2RY12 Q9H244 2/20 0.38
PTPN1 P18031 1/20 0.38
DGAT1 O75907 1/20 0.38
ALDH1A1 P00352 2/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PRKDC P78527 6/20 0.38
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
CETP P11597 1/20 0.37
PIK3CD O00329 3/20 0.37
KDM4E B2RXH2 1/20 0.36
TP53 P04637 1/20 0.36
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15458517 0.94 P2RY12 (0.37) GSK3BCDK5CDK5R1P2RY12PTPN1
SCHEMBL10262086 0.90 CDK5 (0.42) GSK3BCDK5CDK5R1P2RY12PTPN1
SCHEMBL10263140 0.89 PTPN1 (0.40) GSK3BCDK5CDK5R1P2RY12PTPN1
SCHEMBL10262730 0.86 SMN1; SMN2 (0.38) GSK3BCDK5CDK5R1P2RY12PTPN1
SCHEMBL15458500 0.83 CCR5 (0.38) GSK3BCDK5CDK5R1P2RY12PTPN1
SCHEMBL10262089 0.83 PDE10A (0.36) GSK3BCDK5CDK5R1P2RY12PTPN1
SCHEMBL15458520 0.81 PIK3CD (0.36) GSK3BCDK5CDK5R1P2RY12DGAT1
SCHEMBL16301325 0.80 DGAT1 (0.42) PTPN1DGAT1ALDH1A1PRKDCKDM4E
SCHEMBL10293053 0.80 PTPN1 (0.42) PTPN1DGAT1ALDH1A1LMNASMN1; SMN2
SCHEMBL15458588 0.78 PDE10A (0.35) GSK3BCDK5CDK5R1P2RY12DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8691120-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2014-04-08 US disclosed
US-20120170098-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2012-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120170098-A1 CHROMENE COMPOUND CRY2, CRY1, SUN2 GSK3B 3032/4885CDK5 1873/4885CDK5R1 1652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.